Status and phase
Conditions
Treatments
About
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
78 participants in 4 patient groups
Loading...
Central trial contact
Study Director
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal